Limits...
Percutaneous sclerotherapy of renal cysts with a beta-emitting radionuclide, holmium-166-chitosan complex.

Kim JH, Lee JT, Kim EK, Won JY, Kim MJ, Lee JD, Hong SJ - Korean J Radiol (2004 Apr-Jun)

Bottom Line: Eighteen cysts (90%) regressed completely (n=11, 55%) or near-completely (n=7, 35%).No significant complications were encountered.The holmium-166-chitosan complex seems to be useful as a new painless sclerosing agent for the treatment of renal cysts with no significant complications.

View Article: PubMed Central - PubMed

Affiliation: Department of Diagnostic Radiology, Research Institute of Radiological Science, Seoul, Republic of Korea. jtlee@yumc.yonsei.ac.kr

ABSTRACT

Objective: To evaluate the usefulness of a beta-emitting radionuclide (holmium-166-chitosan complex) as a sclerosing agent for the treatment of renal cysts.

Materials and methods: Using 10-30 mCi of holmium-166-chitosan complex, 20 renal cysts in 17 patients (14 male and 3 female patients, ranging in age from 47 to 82 years) were treated by percutaneous sclerotherapy under ultrasonographic guidance. The volume of the cysts before and after the sclerotherapy and the percentage change in volume were calculated in order to evaluate the response to therapy, which was classified as either complete regression (invisible), nearly complete regression (< 15 volume% of initial volume), partial regression (15-50 volume%) or no regression (> 50 volume%).

Results: The follow-up period ranged from 6 to 36 months (mean 28 months). Eighteen cysts (90%) regressed completely (n=11, 55%) or near-completely (n=7, 35%). Partial regression was obtained in one patient (5%) and there was no regression in one patient (5%). No significant complications were encountered.

Conclusion: The holmium-166-chitosan complex seems to be useful as a new painless sclerosing agent for the treatment of renal cysts with no significant complications.

Show MeSH

Related in: MedlinePlus

A 76-year-old man with hematuria.A. This patient underwent renal cyst 95% ethanol sclerotherapy 2 years previously. However, a remnant cortical cyst was noted at the lower pole of the left kidney on sonography, with a calculated volume of 35 ml.B. Follow-up sonography 2 months later showed a significantly reduced cyst volume of 2 ml.C. On follow-up sonography at 14 months, the cyst was undetectable, indicating a complete regression.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2698141&req=5

Figure 2: A 76-year-old man with hematuria.A. This patient underwent renal cyst 95% ethanol sclerotherapy 2 years previously. However, a remnant cortical cyst was noted at the lower pole of the left kidney on sonography, with a calculated volume of 35 ml.B. Follow-up sonography 2 months later showed a significantly reduced cyst volume of 2 ml.C. On follow-up sonography at 14 months, the cyst was undetectable, indicating a complete regression.

Mentions: The mean follow-up period was 28 months (6-36 months). At the initial follow-up after 1-2 month(s), the mean volume of the remaining cysts was 33% of the initial volume. At the 6-month follow-up, the mean volume decreased to 15% of the initial volume. At the 12-month follow-up, the mean volume further decreased to 10% of the initial volume. At the final follow-up, the mean residual volume was 8% of the initial volume. Eighteen cysts (90%) were completely (n=11, 55%) or nearly completely (n=7, 35%) regressed (Figs. 1, 2). Partial regression was obtained in 5% of cases (n=1) and there was no regression in one patient (5%) (Table 1). An organizing hematoma developed in one patient, and this seems to have been the reason for the absence of regression of the cyst in this patient.


Percutaneous sclerotherapy of renal cysts with a beta-emitting radionuclide, holmium-166-chitosan complex.

Kim JH, Lee JT, Kim EK, Won JY, Kim MJ, Lee JD, Hong SJ - Korean J Radiol (2004 Apr-Jun)

A 76-year-old man with hematuria.A. This patient underwent renal cyst 95% ethanol sclerotherapy 2 years previously. However, a remnant cortical cyst was noted at the lower pole of the left kidney on sonography, with a calculated volume of 35 ml.B. Follow-up sonography 2 months later showed a significantly reduced cyst volume of 2 ml.C. On follow-up sonography at 14 months, the cyst was undetectable, indicating a complete regression.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2698141&req=5

Figure 2: A 76-year-old man with hematuria.A. This patient underwent renal cyst 95% ethanol sclerotherapy 2 years previously. However, a remnant cortical cyst was noted at the lower pole of the left kidney on sonography, with a calculated volume of 35 ml.B. Follow-up sonography 2 months later showed a significantly reduced cyst volume of 2 ml.C. On follow-up sonography at 14 months, the cyst was undetectable, indicating a complete regression.
Mentions: The mean follow-up period was 28 months (6-36 months). At the initial follow-up after 1-2 month(s), the mean volume of the remaining cysts was 33% of the initial volume. At the 6-month follow-up, the mean volume decreased to 15% of the initial volume. At the 12-month follow-up, the mean volume further decreased to 10% of the initial volume. At the final follow-up, the mean residual volume was 8% of the initial volume. Eighteen cysts (90%) were completely (n=11, 55%) or nearly completely (n=7, 35%) regressed (Figs. 1, 2). Partial regression was obtained in 5% of cases (n=1) and there was no regression in one patient (5%) (Table 1). An organizing hematoma developed in one patient, and this seems to have been the reason for the absence of regression of the cyst in this patient.

Bottom Line: Eighteen cysts (90%) regressed completely (n=11, 55%) or near-completely (n=7, 35%).No significant complications were encountered.The holmium-166-chitosan complex seems to be useful as a new painless sclerosing agent for the treatment of renal cysts with no significant complications.

View Article: PubMed Central - PubMed

Affiliation: Department of Diagnostic Radiology, Research Institute of Radiological Science, Seoul, Republic of Korea. jtlee@yumc.yonsei.ac.kr

ABSTRACT

Objective: To evaluate the usefulness of a beta-emitting radionuclide (holmium-166-chitosan complex) as a sclerosing agent for the treatment of renal cysts.

Materials and methods: Using 10-30 mCi of holmium-166-chitosan complex, 20 renal cysts in 17 patients (14 male and 3 female patients, ranging in age from 47 to 82 years) were treated by percutaneous sclerotherapy under ultrasonographic guidance. The volume of the cysts before and after the sclerotherapy and the percentage change in volume were calculated in order to evaluate the response to therapy, which was classified as either complete regression (invisible), nearly complete regression (< 15 volume% of initial volume), partial regression (15-50 volume%) or no regression (> 50 volume%).

Results: The follow-up period ranged from 6 to 36 months (mean 28 months). Eighteen cysts (90%) regressed completely (n=11, 55%) or near-completely (n=7, 35%). Partial regression was obtained in one patient (5%) and there was no regression in one patient (5%). No significant complications were encountered.

Conclusion: The holmium-166-chitosan complex seems to be useful as a new painless sclerosing agent for the treatment of renal cysts with no significant complications.

Show MeSH
Related in: MedlinePlus